SPONSORSHIP ALLIANCE NEWS
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care.
First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years .
57% of patients treated with Imfinzi were alive at three years in ADRIATIC Phase III trial.
Artificial intelligence (AI) has the potential to shape nearly every aspect of our lives – including cancer care. At MD Anderson, we see the opportunities and risks associated with the emergence of AI and an ever-increasing amount of data being generated by our cancer research, patient care and clinical operations.
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC). The study, published today in JAMA Oncology, revealed fewer side effects with IMRT, with similar survival outcomes.
New technology presents new opportunities in patient care, something that Yogesh Kumar, Ph.D., knew well when he began researching the use of machine-learning software in cancer treatment. When he received this year’s Mary Ann Harvard NextGen Scholar Award for his work integrating artificial intelligence into radiotherapy, he knew he was on the right track.
Varian, along with Cureus.com, is sponsoring a "CT or CBCT Guided Online Adaptive Radiotherapy (ART) Clinical Case Reports" publishing competition. Eligible case reports will illustrate online ART based on daily CT or CBCT images. Cases may report on ART anywhere in the body, and should highlight a significant advantage of online ART, show the potential to change RT practice, or show that daily ART allows clinicians to treat more effectively compared to a non-adaptive approach. Competition submissions should clearly illustrate, with images, analyses, and clinical outcomes, the advantages of CT/CBCT-guided online ART compared to non-ART treatment.
Submission Deadline: Tuesday, July 23, 2024
Submission site closes at 5:00 pm ET
For questions contact David Schaal at david.schaal@varian.com
Congratulations to Professor Alexander Muacevic, Dr. Markus Kufeld and the team at ERCM.
Congratulations to Alexander Muacevic, Antonio Santacroce, Felix Ehret and the rest of the team at European Radiosurgery Center - Munich (ERCM) on publishing the first use of ZAP-X gyroscopic radiosurgery for uveal melanoma.
In the overall trial population, survival results numerically favoured AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan but did not reach statistical significance.
TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population.
Results support applications currently under review by regulatory authorities globally including in the US and EU.
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
AEx Rewind Webinar: SBRT for Central and Ultra-Central Early-Stage Inoperable Non-Small Cell Lung Cancer is now available on demand. This informative session explores treatment options for patients who are medically inoperable and have central or ultra-central lung cancer (CLC/UCLC). Don't miss this opportunity to gain valuable insights into managing CLC/UCLC patients through SBRT.
Elekta and MIM Software Inc., a leading provider of medical imaging management and artificial intelligence solutions, recently acquired by GE HealthCare, announce their collaboration to combine best-of-breed solutions for advanced treatment planning in the delivery of radiation therapy. The strategic collaboration aims to accelerate innovation in software solutions that will benefit clinics with improved workflows, higher throughput, and enhanced user experience, while for patients, provide greater precision in their treatment and less time spent at the hospital.
Future Brain Therapy: Cutting-edge radiotherapy device offers hope for Chinese brain tumor patients. recently received official treatment approval in China. Watch the news segment here.
A cost-effective, rapid deployment of state-of-the-art radiosurgery made possible with the vault-free, cobalt-free ZAP-X. Congratulations to the teams at Miami Cancer Institute and Baptist Health for initiating patient treatments in this entirely novel and pioneering setting. Learn more how ZAP-X creates elite neuro-oncology programs anywhere, everywhere. Visit https://zapsurgical.com/
Neurosciences and Spine Group in Vestal to Bring Access to State-of-the-Art Radiosurgery to Southern New York and Surrounding Communities
100 patients with wide ranging indications including multiple mets, vestibular schwannoma, meningioma, AVM, etc. Request a copy: info@zapsurgical.com.
Milestone Reinforces Mutual Commitment to Advancing Healthcare Through Greater Access to State-of-the-Art Medical Technologies.
See stunning video footage of the new ZAP-X program at Hacettepe University.
RefleXion and Limbus AI, a provider of software solutions for cancer radiation therapy, announced a technology integration agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system. This integration will reduce the most significant bottleneck in the patient treatment planning process, which involves delineating the tumor target from surrounding critical organs and other healthy tissue.
Frameless LINAC radiosurgery directed to the sensory region of selected nerve roots has been recently described as a novel treatment option to relieve severe spasticity . A prospective Sham-Controlled Trial of Dorsal Root Rhizotomy Stereotactic Radiosurgery versus Standard of Care for Spasticity Associated with Stroke, Spinal Cord Injury and Cerebral Palsy is currently underway to provide a solid assessment about the efficacy and safety of this novel treatment.
New data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois supports the use of the CyberKnife® System in treating high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of the disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams. "Health-Related Quality of Life Following Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer." [https://www.rssevents.org/fsPopup.asp?PosterID=658464&mode=posterInfo] "Acute Toxicity Following PSMA-Directed Focal Salvage Robotic SBRT for Local Recurrences Following Prior Robotic Prostate SBRT." [https://www.rssevents.org/fsPopup.asp?PosterID=658489&mode=posterInfo]
Stereotactic ablative radiotherapy (SABR) has shown benefit in early-stage non–small cell lung cancer (NSCLC) and has also shown clinical benefit in combination with immunotherapy, making it a viable treatment option to consider, according to a presentation given by Joe Y. Chang, MD, PhD, during The Radiation Oncology Summit: ACRO 2024. Chang explained that immunotherapy plus SABR could be evaluated as a curative approach.
As of January 2024, Geisinger is now equipped to conduct GammaTile Therapy procedures. “GammaTile Therapy uses radioactive cesium seeds embedded in collagen sheets to deliver safe and effective radiotherapy for patients with a wide variety of brain tumors,” said Charles T. Lee, MD, radiation oncology, Geisinger. GammaTile Therapy is best for patients with recurring tumors that have previously been treated with radiation as it allows the safe delivery of higher doses than would be allowed by traditional approaches. “The GammaTile is placed during the time of surgery and reduces the number of trips the patient needs to make to their local radiation treatment facility,” added Dr. Lee. Geisinger will continue to provide updates via the Radiosurgery Society.
Perlmutter Cancer Center at NYU - Long Island Radiation Oncology announced that it has begun enrolling and treating eligible CyberKnife patients with prostate cancer on an IRB-approved protocol that will last just two treatments rather than the usual five. They will also be integrating genomics into this particular study to intensify or deintensify the radiation based on a patient's personalized genomic pattern. Expect to hear more about this study at the free screening and education day that is being scheduled to take place in NYU's Mineola location in the spring.
The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre. Working together, MD Anderson and the IAEA aim to enhance radiation oncology, radiation physics, radiology, nuclear medicine and nutrition globally. MD Anderson operates the most comprehensive radiation oncology facility in the world and will be the first IAEA Collaborating Centre in the United States focused on health care.
As the sponsor of the SGRT Community, Vision RT is pleased to announce the full agenda for this year's annual meeting. What better way to learn how SGRT can help improve the safety, effectiveness and efficiency of your workflows than to reserve your place in the sun at this free, in-person learning event, taking place June 6-7, 2024 at the Scottsdale Plaza Resort & Villas, in Phoenix, Arizona. Our theme, 'Stay Ahead With SGRT', emphasizes the critical advantages of keeping up with the latest developments in the use of Surface Guidance - throughout the entire workflow of Sim, Plan, Treat, and Dose. SGRT has gone from "nice-to-have" to indispensable, and we'll have a full slate of expert SGRT users from some of the most prominent clinics in the world offering you their guidance and practical experience.
City of Hope has treated their first patient using SCINTIX biology-guided radiotherapy. Learn more about this exciting milestone in their recent blog.
The BIOGUIDE-X study is the newest addition to the growing body of scientific evidence supporting SCINTIX biology-guided radiotherapy. Click below to read more about this article, published in the Red Journal, which covers the clinical investigation and novel trial design that led to FDA clearance for SCINTIX therapy in primary and metastatic lung and bone tumors.
Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution. By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators. HyperSight empowers clinicians to accurately tailor treatments to each individual patient with the goal of improving patient outcomes.